OPTFSNA
AVTX icon

Old Point Trust & Financial Services N A’s Avalo Therapeutics AVTX Stock Holding History

Old Point Trust & Financial Services N A’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$22 – 373
2024
Q1 		$22 Buy
+1
New +$5 ﹤0.01% 554

Other funds holding AVTX

LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Old Point Trust & Financial Services N A's AVTX Position: Q2 2024 in Review

Old Point Trust & Financial Services N A sold out of Avalo Therapeutics (AVTX) in Q2 2024, closing a stake of 1 share — an estimated $22 sold.

Old Point Trust & Financial Services N A first reported a position in AVTX in Q1 2024 and held it in 1 quarter. The position peaked at $22 in Q1 2024. 21 funds tracked by Wall St. Rank hold AVTX as of Q2 2024.

  • Old Point Trust & Financial Services N A reported no remaining Avalo Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Old Point Trust & Financial Services N A sold 1 Avalo Therapeutics share in Q2 2024, an estimated $22.
  • Old Point Trust & Financial Services N A first reported a position in Avalo Therapeutics in Q1 2024 and held it in 1 quarter.
  • Old Point Trust & Financial Services N A's Avalo Therapeutics position peaked at $22 in Q1 2024.
  • 21 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2024.

Based on Old Point Trust & Financial Services N A's 13F filing for Q2 2024, filed 13 Aug 2024.